<< Back to Investments

AXIM Biotechnologies™

AXIM Biotechnologies™ is an innovative biotechnology company focusing on research, development and production of pharmaceutical, nutraceutical and cosmetic products where we prioritize the well-being of our customers while embracing a solid fiscal strategy.

Connect


AXIM Biotechnologies
Boelewerf 32, Unit 3
2987 VD Ridderkerk
The Netherlands
+31 10 8209 227
Contact
www.aximbiotech.com

August 3, 2017

Medical Marijuana, Inc. Major Investment AXIM Biotech Enters Clinical Study Agreement with University of British Columbia to Begin Clinical Trial On CBD Chewing Gum For Treatment of Drug-Related Psychosis

SAN DIEGO, Aug. 3, 2017 /PRNewswire/ — Medical Marijuana, Inc. (OTC: MJNA), the first publicly traded cannabis company in the United States, today announced that its major investment company AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC: AXIM) has entered into a Clinical Study Agreement (CSA) with

July 27, 2017

Medical Marijuana, Inc Major Investment AXIM Biotech Enters Agreement With Israel-Based CRO To Begin Clinical POC Study For Treatment Of Restless Leg Syndrome

SAN DIEGO, July 27, 2017 /PRNewswire/ — Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States, today announced that its major investment AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC: AXIM) has entered into a Services Agreement with an Israel-based contract research organization (CRO)

July 21, 2017

AXIM Biotech Enters Services Agreement With Israel-Based CRO to Begin Clinical POC Study on CBD and Gabapentin Chewing Gum for Treatment of Restless Leg Syndrome

AXIM Biotechnologies, Inc. (AXIM Biotech) AXIM, +2.42% a world leader in cannabinoid research and development, today announced that it has entered into a Services Agreement with an Israel-based contract research organization (CRO) to begin a clinical proof of concept study (POC) with its cannabidiol

June 27, 2017

Reuters Features Medical Marijuana, Inc.’s Major Investment Company AXIM Biotech In Article Citing Company’s Development Of Marijuana-Based Painkiller To Combat Opioid Crisis

NEW YORK, June 27, 2017 — Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States, announced today that its major investment company AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC: AXIM), a world leader in cannabinoid research and

May 17, 2017

SeeThruEquity Initiates Coverage On Medical Marijuana, Inc. Investment Company AXIM Biotech (OTC: AXIM) With A Target Price Of $17.00

SAN DIEGO, May 17, 2017 /PRNewswire/ — Medical Marijuana, Inc. (OTC PINK:MJNA), the first-ever publicly traded cannabis company in the United States, announced today that its investment company AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC: AXIM) received coverage initiation from SeeThruEquity, a

May 16, 2017

AXIM Biotech Clinical Study to Develop Bioequivalent Product to Marinol Listed on Clinicaltrials.gov

NEW YORK, May 15, 2017 –– AXIM® Biotechnologies, Inc. (AXIM® Biotech) AXIM, +37.64% a world leader in cannabinoid research and development, today announced that information on the company’s Bioavailability Study on Dronabinol in a controlled-release, functional chewing gum form is now

May 3, 2017

Medical Marijuana, Inc. Major Investment AXIM Biotech Moves Forward With Development Of MedChew Rx Pharmaceutical Chewing Gum

SAN DIEGO, May 3, 2017 — Medical Marijuana, Inc. (MJNA), the first-ever publicly traded cannabis company in the United States, announced today that its major investment company AXIM® Biotechnologies, Inc.’s (AXIM® Biotech) (AXIM) product development partner Quay Pharmaceuticals Ltd. (“Quay

March 28, 2017

Medical Marijuana, Inc. Major Investment AXIM Biotech Enters Term Sheet Agreement With U.S. API Company To Develop Bioequivalent Product To Marinol

SAN DIEGO, March 28, 2017 — Medical Marijuana, Inc. (OTC:MJNA), the first-ever publicly traded cannabis company in the United States, announced today that its major investment company AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTCQB:AXIM), has entered into a Term Sheet Agreement with a U.S.-based controlled-substances API

March 21, 2017

Medical Marijuana, Inc. Investment AXIM Biotech Retains Ora To Manage Upcoming Product Development And Clinical Trials On Glaucoma And Dry Eye Indications

NEW YORK, March 21, 2017 — Medical Marijuana, Inc. (OTC:MJNA), the first-ever publicly traded cannabis company in the United States, announced today that its major investment company AXIM®Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, has

March 7, 2017

Medical Marijuana, Inc. Investment AXIM® Biotech Announces Enrolled Patients Begin Phase II Trial For The Treatment Of Irritable Bowel Syndrome (IBS) With CanChew Plus® Cannabidiol (CBD) Chewing Gum

NEW YORK, March 7, 2017 — Medical Marijuana, Inc. (OTC:MJNA), the first-ever publicly traded cannabis company in the United States, announced today that its major investment company AXIM® Biotechnologies, Inc. (AXIM® Biotech) (AXIM) has enrolled 40 patients and commenced its Phase

March 1, 2017

Medical Marijuana, Inc. Clarifies Operations Unaffected by White House Statements Hinting at Recreational Marijuana Crackdown

SAN DIEGO, March 1, 2017 — Medical Marijuana, Inc. (OTC:MJNA), the first publicly traded cannabis company in the United States, is reassuring customers, shareholders, and the public that the company’s operations in the federally legal hemp cannabidiol (CBD) market are unaffected by

January 18, 2017

AXIM® Biotech Enters IBS Clinical Trial for CanChew CBD Chewing Gum

NEW YORK, Jan 18, 2017 (GLOBE NEWSWIRE via COMTEX) — AXIM® Biotechnologies, Inc. (AXIM® Biotech) AXIM, +25.67% a world leader in cannabinoid research and development, entered a clinical trial on treating irritable bowel syndrome (IBS) with the company’s CanChew Plus®

January 10, 2017

AXIM® Biotech Attends Biotech Showcase and J.P. Morgan Healthcare Conferences in San Francisco

NEW YORK, Jan 10, 2017 — AXIM Biotechnologies, Inc. (AXIM Biotech) AXIM, +23.30% a world leader in cannabinoid research and development, today announced that George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM Biotech, is meeting with

January 9, 2017

Medical Marijuana, Inc. Investment AXIM® Biotech Receives Positive PK Data Results for CanChew Plus(R) CBD Gum

AXIM Biotechnologies Announces Positive Pharmacokinetic (PK) Data Results on Proprietary Delivery Method for Cannabinoids in Chewing Gum SAN DIEGO, CA — (Marketwired) — 01/09/17 — Medical Marijuana, Inc.(OTC PINK:MJNA), the first-ever publicly traded cannabis company in the United States, announced

January 6, 2017

Article Names Medical Marijuana, Inc. and AXIM® Biotech as Two of “10 Largest Marijuana Companies Raking in Huge Profits”

SAN DIEGO, CA — (Marketwired) — 01/06/17 — Medical Marijuana, Inc.(OTC PINK:MJNA), the first publicly traded cannabis company in the United States, today announced that the Company was featured in a recent High Times article, “10 Largest Marijuana Companies Raking

January 4, 2017

AXIM® BIOTECH RECEIVES POSITIVE PK DATA RESULTS FOR CANCHEW PLUS® CBD GUM

NEW YORK – Jan. 04, 2017 – AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC: AXIM), a world leader in cannabinoid research and development, received positive pharmacokinetic (PK) data results on its CanChew Plus® CBD Gum, and gears up for clinical trial

December 13, 2016

Forbes Features Medical Marijuana, Inc. in Article Citing Company’s Sales Data After Starting CBD Market ‘That Could Grow 700% by 2020’

Article Features Positive Growth Stats for the CBD Market and Information on Medical Marijuana, Inc. Products, Investments and Subsidiary Companies SAN DIEGO, CA–(Marketwired – December 13, 2016) – Medical Marijuana, Inc. (OTC PINK: MJNA), the first-ever publicly traded cannabis company

November 29, 2016

Medical Marijuana, Inc.’s Investment AXIM® Biotech Files IP Application on Proprietary Method to Extract High-Purity THC

Company’s major investment company announces filing of protection for proprietary method of THC extraction that will achieve highest THC purity level on the market. SAN DIEGO – Nov. 29, 2016 – Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded

November 22, 2016

Axim® Biotechnologies, Inc. Donates Flagship CanChew Gum to U.S. Pain Foundation to Help Chronic Pain Sufferers

NEW YORK, Nov. 22, 2016 (GLOBE NEWSWIRE) — AXIM®Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that it has donated 3,200 pieces of its hemp-derived CBD functional chewing gum CanChew® to the U.S.

November 16, 2016

U.S. Patent Allowance Granted to Medical Marijuana, Inc.’s Investment AXIM(R) Biotech for Use of All Cannabinoids in Its Controlled Release Chewing Gum

SAN DIEGO, CA–(Marketwired – November 16, 2016) – Medical Marijuana, Inc. (OTC PINK: MJNA) announced today that its major investment AXIM® Biotechnologies, Inc. (AXIM® Biotech) (AXIM), a world leader in hemp cannabinoid research and development, today announced that the United

AXIM Biotechnologies™ is focused on developing a portfolio of ventures in the following areas: